State law can’t compel ‘patent dance’, rules Federal Circuit
15-12-2017
BIO 2017: Panellists talk Amgen Sandoz biosimilar battle
23-06-2017
Fed Circuit erred in Sandoz v Amgen, says solicitor general
28-02-2017
sprng23 / iStockphoto.com
The US Supreme Court has ruled that biosimilar applicants may provide notice to the manufacturer before obtaining a licence from the Food and Drug Administration (FDA) for their biosimilars.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
SCOTUS, Amgen, Sandoz, Neupogen, biologics, biosimilar, FDA, BPCIA, US Supreme Court
